146 related articles for article (PubMed ID: 25835095)
1. Functional proteomics of the epigenetic regulators ASXL1, ASXL2 and ASXL3: a convergence of proteomics and epigenetics for translational medicine.
Katoh M
Expert Rev Proteomics; 2015 Jun; 12(3):317-28. PubMed ID: 25835095
[TBL] [Abstract][Full Text] [Related]
2. Functional and cancer genomics of ASXL family members.
Katoh M
Br J Cancer; 2013 Jul; 109(2):299-306. PubMed ID: 23736028
[TBL] [Abstract][Full Text] [Related]
3. Identification and characterization of ASXL3 gene in silico.
Katoh M; Katoh M
Int J Oncol; 2004 Jun; 24(6):1617-22. PubMed ID: 15138607
[TBL] [Abstract][Full Text] [Related]
4. DNA methylation signature associated with Bohring-Opitz syndrome: a new tool for functional classification of variants in ASXL genes.
Awamleh Z; Chater-Diehl E; Choufani S; Wei E; Kianmahd RR; Yu A; Chad L; Costain G; Tan WH; Scherer SW; Arboleda VA; Russell BE; Weksberg R
Eur J Hum Genet; 2022 Jun; 30(6):695-702. PubMed ID: 35361921
[TBL] [Abstract][Full Text] [Related]
5. The Role of Additional Sex Combs-Like Proteins in Cancer.
Micol JB; Abdel-Wahab O
Cold Spring Harb Perspect Med; 2016 Oct; 6(10):. PubMed ID: 27527698
[TBL] [Abstract][Full Text] [Related]
6. The HARE-HTH and associated domains: novel modules in the coordination of epigenetic DNA and protein modifications.
Aravind L; Iyer LM
Cell Cycle; 2012 Jan; 11(1):119-31. PubMed ID: 22186017
[TBL] [Abstract][Full Text] [Related]
7. WTIP interacts with ASXL2 and blocks ASXL2-mediated activation of retinoic acid signaling.
Khan FF; Li Y; Balyan A; Wang QT
Biochem Biophys Res Commun; 2014 Aug; 451(1):101-6. PubMed ID: 25065743
[TBL] [Abstract][Full Text] [Related]
8. Identification and characterization of ASXL2 gene in silico.
Katoh M; Katoh M
Int J Oncol; 2003 Sep; 23(3):845-50. PubMed ID: 12888926
[TBL] [Abstract][Full Text] [Related]
9. ASXL gain-of-function truncation mutants: defective and dysregulated forms of a natural ribosomal frameshifting product?
Dinan AM; Atkins JF; Firth AE
Biol Direct; 2017 Oct; 12(1):24. PubMed ID: 29037253
[TBL] [Abstract][Full Text] [Related]
10. Gene methylation in gastric cancer.
Qu Y; Dang S; Hou P
Clin Chim Acta; 2013 Sep; 424():53-65. PubMed ID: 23669186
[TBL] [Abstract][Full Text] [Related]
11. Understanding the phenotypic spectrum of ASXL-related disease: Ten cases and a review of the literature.
Cuddapah VA; Dubbs HA; Adang L; Kugler SL; McCormick EM; Zolkipli-Cunningham Z; Ortiz-González XR; McCormack S; Zackai E; Licht DJ; Falk MJ; Marsh ED
Am J Med Genet A; 2021 Jun; 185(6):1700-1711. PubMed ID: 33751773
[TBL] [Abstract][Full Text] [Related]
12. Unlike ASXL1 and ASXL2 mutations, ASXL3 mutations are rare events in acute myeloid leukemia with t(8;21).
Duployez N; Micol JB; Boissel N; Petit A; Geffroy S; Bucci M; Lapillonne H; Renneville A; Leverger G; Ifrah N; Dombret H; Abdel-Wahab O; Jourdan E; Preudhomme C
Leuk Lymphoma; 2016; 57(1):199-200. PubMed ID: 25856206
[No Abstract] [Full Text] [Related]
13. Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex.
Balasubramani A; Larjo A; Bassein JA; Chang X; Hastie RB; Togher SM; Lähdesmäki H; Rao A
Nat Commun; 2015 Jun; 6():7307. PubMed ID: 26095772
[TBL] [Abstract][Full Text] [Related]
14. Systematic knockdown of epigenetic enzymes identifies a novel histone demethylase PHF8 overexpressed in prostate cancer with an impact on cell proliferation, migration and invasion.
Björkman M; Östling P; Härmä V; Virtanen J; Mpindi JP; Rantala J; Mirtti T; Vesterinen T; Lundin M; Sankila A; Rannikko A; Kaivanto E; Kohonen P; Kallioniemi O; Nees M
Oncogene; 2012 Jul; 31(29):3444-56. PubMed ID: 22120715
[TBL] [Abstract][Full Text] [Related]
15. The ASXL-BAP1 axis: new factors in myelopoiesis, cancer and epigenetics.
Abdel-Wahab O; Dey A
Leukemia; 2013 Jan; 27(1):10-5. PubMed ID: 23147254
[TBL] [Abstract][Full Text] [Related]
16. Role of Asxl1 in kidney podocyte development via its interaction with Wtip.
Moon S; Um SJ; Kim EJ
Biochem Biophys Res Commun; 2015 Oct; 466(3):560-6. PubMed ID: 26385183
[TBL] [Abstract][Full Text] [Related]
17. Multiomics of Bohring-Opitz syndrome truncating ASXL1 mutations identify canonical and noncanonical Wnt signaling dysregulation.
Lin I; Wei A; Awamleh Z; Singh M; Ning A; Herrera A; ; Russell BE; Weksberg R; Arboleda VA
JCI Insight; 2023 May; 8(10):. PubMed ID: 37053013
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic targeted therapy of stabilized BAP1 in ASXL1 gain-of-function mutated leukemia.
Wang L; Birch NW; Zhao Z; Nestler CM; Kazmer A; Shilati A; Blake A; Ozark PA; Rendleman EJ; Zha D; Ryan CA; Morgan MAJ; Shilatifard A
Nat Cancer; 2021 May; 2(5):515-526. PubMed ID: 35122023
[TBL] [Abstract][Full Text] [Related]
19. Monoubiquitination of ASXLs controls the deubiquitinase activity of the tumor suppressor BAP1.
Daou S; Barbour H; Ahmed O; Masclef L; Baril C; Sen Nkwe N; Tchelougou D; Uriarte M; Bonneil E; Ceccarelli D; Mashtalir N; Tanji M; Masson JY; Thibault P; Sicheri F; Yang H; Carbone M; Therrien M; Affar EB
Nat Commun; 2018 Oct; 9(1):4385. PubMed ID: 30349006
[TBL] [Abstract][Full Text] [Related]
20. Focusing on frequent ASXL1 mutations in myeloid neoplasms, and considering rarer ASXL2 and ASXL3 mutations.
Oak JS; Ohgami RS
Curr Med Res Opin; 2017 Apr; 33(4):781-782. PubMed ID: 28097878
[No Abstract] [Full Text] [Related]
[Next] [New Search]
